According to 10 trials that included 13,715 diabetics taking Avandia, Actos, or neither, the two drugs reduced bone density in the spine and hips of women. According to their estimates, this loss of bone density doubles the risk of fractures in women taking either drug.
Lead researcher Dr. Yoon Loke, a clinical senior lecturer at the University of East Anglia in Norwich, said "Women who are taking these drugs should reconsider the options." In the press release, Loke suggested that women are affected because of an interaction between the drugs and estrogen, which weakens bones in women.
GlaxoSmithKline, the maker of Avandia, said in a press release that this study merely reiterates information that is already known and printed on Avandia's label. The information is not on their marketing material web page (http://www.avandia.com/?banner...;rotation_s=30495928).
That web page does mention the recently discussed heart disease effects. However, here's the link to the complete subscribing information: http://us.gsk.com/products/assets/us_avandia.pdf